

**Abstract**

*Study objective:* To evaluate the diagnostic value of four different tumor markers: cancer antigen 125 (CA-125), carcinoembryonic antigen (CEA), cytokeratin 19 fragment (CYFRA 21-1) and neuron specific enolase (NSE) in patients with malignant and non-malignant pleural effusion.

*Material and methods:* One hundred and two patients with pleural effusion treated in the University Hospital in Warsaw between 2001 and 2003 were studied. They underwent an extensive, diagnostic work-up in order to determine the pleural effusion etiology. Patients with known pleural fluid etiology were labeled as the study group and submitted for further analysis. Pleural fluid and serum samples for CA-125, CEA, CYFRA 21-1 and NSE measurements were collected during the first thoracentesis, centrifuged, and frozen until further use. Pleural fluid and serum concentration of tumor markers were assessed by electrochemiluminescence methods using commercial kits.

*Results:* 74 patients (32 M, 42 F; mean age 65 ±14 years) composed the final study group. Exudative pleural effusion was found in 62 patients; of these 36 were malignant (48.6% of all effusions), 20 parapneumonic (or pleural empyema), and 6 tuberculous. In 12 patients, pleural transudate was diagnosed. The highest diagnostic sensitivity for malignant pleural effusion was found for NSE (94.4% and 80.0% in the pleural fluid and serum, respectively). However, the specificity of NSE measurement was relatively low (36.1% and 47.4% in pleural fluid and serum, respectively). The most specific markers of malignant pleural fluid etiology were pleural fluid CYFRA 21-1 and CEA levels (92.1% and 92.1%, respectively). CA-125 was found to be the most specific serum marker of pleural malignancies (78.9%). The AUC for combined pleural markers was 0.89, combined serum markers 0.82, combined ratio pleural/serum markers 0.88.

*Conclusions:* There are significant differences between the diagnostic value of various pleural fluid and serum markers. Overall, pleural fluid markers are superior to serum markers in determining the pleural fluid etiology. A combination of two or more tumor markers may help improve their diagnostic accuracy. Pleural fluid and serum measurements of different tumor markers play a limited role in the differentiation between malignant and non-malignant pleural effusions.

*Key words:* pleural effusion, cancer antigen-125, neuron specific enolase, carcinoembryonic antigen

**INTRODUCTION**

Pleural effusion (PE) may occur in many different diseases and is often a diagnostic challenge. One of the main issues in the differential diagnosis of PE is distinguishing exudates from transudates. This requires the assessment of the physicochemical properties of the fluid and comparison of selected biochemical parameters (e.g., total protein, lactate dehydrogenase activity, bilirubin, and cholesterol) in the fluid and serum. Determining the nature of PE (exudate or transudate) allows reducing the list of potential PE causes and indicates the direction for further diagnosis.

Another important clinical issue is the etiology of effusion – malignant or benign. This is crucial for PE management and prognosis. Cytological examination of PE samples is a simple and widely used diagnostic tool for differentiating the origin of the pleural fluid. It is characterized by a high specificity; however it has a relatively low sensitivity (40-87%, mean ca 60%) [1]. Confirming the malignant PE etiology in the patient with a negative cytological PE examination requires more complicated diagnostic procedures, such as needle pleural biopsy or thoracoscopy. Thus, in a number of patients the distinction between malignant and non-malignant PE may be difficult and limited by the risk related to invasive procedures. Tumor markers seem to be a promising alternative and have been proposed to aid in the differentiation of the PE etiology. These include carcinoembryonic antigen (CEA), cancer antigens: CA-125, CA 15-3, CA 19-9, CA 72-4, cytokeratin fragments (CYFRA 21-1), neuron specific enolase (NSE), and squamous cell carcinoma antigen (SCCA). However, the clinical value of these markers is still unclear.

Several studies revealed that the level of some tumor markers in the pleural fluid and/ or serum is a reliable predictor of malignant PE etiology [2]. Other studies show that the sensitivity, specificity and diagnostic accuracy of different tumor markers are quite
who refused further evaluation) and those patients were of effusion was uncertain (these included 10 subjects). Analysis. In the remaining 28 patients, the etiology of pulmonary venous congestion. Seventy-four patients failure was recognized in patients with physical signs of heart failure (peripheral edema, crepitations on chest auscultation), cardiomegaly, and radiographic signs of heart failure (pleural transudate formation was related to liver cirrhosis and nephrotic syndrome. Distribution of primary tumor sites in malignant PE group was as follows: breast (n=10), lung (n=10), hematologic malignancies (n=4), uterus (n=3), malignant pleural mesothelioma (n=2), stomach (n=2), thyroid gland (n=2), and others (n=3).

All patients with non-malignant pleural exudates and patients with pleural transudates were labeled as the non-malignant PE group and compared with the patients with malignant PE. The mean age of the patients with malignant PE was 63 ±13 y. There were 10 and 20 males (14% and 27%) in the malignant and non-malignant PE group, respectively. The comparison of median (and IQR) values of CA-125, CEA, CYFRA 21-1, and NSE concentrations in the pleural fluid (P), serum (S), and the P/R ratio of the respective markers in malignant and non-malignant patients are presented in Table 1.

The median pleural fluid concentrations of the investigated tumor markers were significantly higher in malignant exudates compared with non-malignant effusions, with the exception of CA-125 which was similar. An analysis of the serum concentrations revealed comparable values of CA-125 and NSE in both groups, while the CEA and CYFRA 21-1 levels were significantly higher in malignant effusions. The pleural fluid/serum concentration ratios were similar for all markers in both investigated groups, with the exception of CEA which was significantly higher in the malignant group.

**RESULTS**

There were 32 males (43%) and 42 (57%) females in the study group (mean age 65 ±14 years). Unilateral pleural effusion (PE) was found in 66 patients, while 6 patients had a bilateral effusion. In 62 patients, pleural fluid met the criteria for exudates; in the remaining 12 patients pleural transudate was diagnosed. The etiologic diagnosis of 62 pleural exudates was as follows: 36 malignant PE (48.6% of all effusions), 20 parapneumonic PE (or pleural empyema) and 6 tuberculous PE. Heart failure was responsible for the vast majority of pleural transudates (9 patients). In 3 patients, pleural transudate formation was related to liver cirrhosis or nephrotic syndrome. Distribution of primary tumor sites in malignant PE group was as follows: breast (n=10), lung (n=10), hematologic malignancies (n=4), uterus (n=3), malignant pleural mesothelioma (n=2), stomach (n=2), thyroid gland (n=2), and others (n=3).

All patients with non-malignant pleural exudates and patients with pleural transudates were labeled as the non-malignant PE group and compared with the patients with malignant PE. The mean age of the patients with malignant PE was 63 ±13 y. There were 10 and 20 males (14% and 27%) in the malignant and non-malignant PE group, respectively. The comparison of median (and IQR) values of CA-125, CEA, CYFRA 21-1, and NSE concentrations in the pleural fluid (P), serum (S), and the P/R ratio of the respective markers in malignant and non-malignant patients are presented in Table 1.
Table 1. Tumor marker concentration in pleural fluid (P), serum (S), and the P/S ratio (R) in patients with malignant vs. non-malignant PE.

|                     | Malignant effusion (n=36) | Non-malignant effusion (n=38) | P     |
|---------------------|---------------------------|-------------------------------|-------|
| CA-125(P)           | 965.9 (412.9-1790.5)      | 518.5 (297.7-796.6)           | NS    |
| CEA(P)              | 12.1 (1.9-79.2)           | 1.1 (0.8-1.6)                 | <0.001|
| CYFRA 21-1(P)       | 27.5 (14.8-213.6)         | 12.8 (5.0-31.5)               | <0.05 |
| NSE(P)              | 2.7 (0.9-10.5)            | 1.0 (0.2-4.3)                 | <0.05 |
| CA-125(S)           | 180.7 (68.4-404.8)        | 135.8 (60.6-191.4)            | NS    |
| CEA(S)              | 4.1 (1.7-28.1)            | 2.3 (1.5-3.4)                 | <0.05 |
| CYFRA 21-1(S)       | 4.6 (2.1-16.6)            | 1.9 (1.2-2.7)                 | <0.001|
| NSE(S)              | 15.8 (10.9-30.5)          | 11.9 (8.1-18.4)               | NS    |
| CA-125(R)           | 4.6 (2.6-7.1)             | 3.7 (2.6-6.9)                 | NS    |
| CEA(R)              | 1.4 (0.8-3.9)             | 0.5 (0.4-0.7)                 | <0.001|
| CYFRA 21-1(R)       | 0.1 (0.06-0.8)            | 0.1 (0.02-0.3)                | NS    |
| NSE(R)              | 6.9 (2.1-11.1)            | 6.9 (2.6-20.5)                | NS    |

Values are presented as median (with IQR in parenthesis). CA-125 (mU/ml), CEA (µg/ml), CYFRA 21-1 (ng/ml), and NSE (ng/ml).

Table 2. Receiver operating characteristics (ROC) for the four tumor markers with their cut-off points for achieving the best diagnostic accuracy.

|                | Cut-off | Sensitivity % (95% CI) | Specificity % (95% CI) | PPV % (95% CI) | NPV % (95% CI) | Accuracy | AUC    |
|----------------|---------|------------------------|------------------------|----------------|----------------|----------|--------|
| CA-125(P)      | 1017    | 50.0 (32.9-67.1)       | 81.6 (65.7-92.4)       | 72.0 (50.6-87.9) | 63.3 (48.3-76.6) | 0.64     |        |
| CEA(P)         | 2.71    | 72.2 (54.8-85.8)       | 92.1 (78.6-98.3)       | 89.7 (72.2-97.9) | 77.8 (62.9-88.8) | 0.83     |        |
| CYFRA 21-1(P)  | 74.7    | 41.7 (25.5-59.2)       | 92.1 (78.6-98.3)       | 83.3 (57.7-96.6) | 62.5 (48.5-75.1) | 0.69     |        |
| NSE(P)         | 0.22    | 94.4 (81.1-99.3)       | 36.1 (20.8-53.8)       | 59.6 (45.8-72.4) | 86.7 (59.5-98.3) | 0.65     |        |
| CA-125(S)      | 214.2   | 44.4 (27.9-61.9)       | 78.9 (62.7-90.4)       | 66.7 (44.7-84.4) | 60.0 (45.2-73.6) | 0.60     |        |
| CEA(S)         | 3.27    | 61.1 (43.5-76.9)       | 73.7 (54.1-84.6)       | 68.7 (50.0-83.9) | 66.7 (50.5-80.4) | 0.65     |        |
| CYFRA 21-1(S)  | 2.42    | 72.2 (54.8-85.8)       | 73.7 (56.9-86.6)       | 72.2 (54.8-85.8) | 73.7 (56.9-86.6) | 0.78     |        |
| NSE(S)         | 10.6    | 80.6 (64.0-91.8)       | 47.4 (31.0-64.2)       | 59.2 (44.2-73.0) | 72.0 (50.6-87.9) | 0.62     |        |
| CA-125(R)      | 11.16   | 22.2 (10.1-39.2)       | 94.7 (82.3-99.4)       | 80.0 (44.4-97.5) | 56.2 (43.3-68.6) | 0.54     |        |
| CEA(R)         | 0.83    | 69.4 (51.9-83.7)       | 89.5 (75.2-97.1)       | 86.2 (68.3-96.1) | 75.6 (60.5-87.1) | 0.84     |        |
| CYFRA 21-1(R)  | 11.4    | 77.8 (60.8-89.9)       | 42.1 (26.3-59.2)       | 56.0 (41.3-70.0) | 66.7 (44.7-84.4) | 0.54     |        |
| NSE(R)         | 0.04    | 83.3 (67.2-93.6)       | 44.7 (28.6-61.7)       | 58.8 (44.2-72.4) | 73.9 (51.0-90.1) | 0.62     |        |

P - Pleural fluid values, S – Serum values, R – Ratio between pleural fluid and serum. PPV - Positive Predictive Value; NPV - Negative Predictive Value.
The receiver operating characteristics for the four investigated tumor markers (measured in the pleural fluid (P), serum (S), and P/S ratio (R)) with their cut-off points for achieving the best diagnostic accuracy are presented in Table 2. The ROC curves for all the investigated parameters are presented in Fig. 1.

To assess the clinical usefulness of combined sensitivity and specificity we calculated the Youden index for every investigated parameter. Fig. 2 presents the results of the Youden index in a decreasing order; the highest corresponding to higher clinical value, with its respective sensitivity and specificity. The four highest values calculated with the help of the Youden index are presented on a ROC curve. The highest clinical value was demonstrated for the CEA pleural and serum concentrations, along with the P/S ratio (Fig. 3A).

A combination of the ROC curves for all investigated parameters (pleural fluid and serum tumor marker concentrations with the P/S ratio) resulted in a higher sensitivity and specificity. When at least two pleural fluid marker levels were above their cut-off points, the sensitivity and specificity achieved 91.7% and 86.6%, respectively. An analogous analysis for the serum markers revealed the sensitivity and specificity of 86.1% and 71.1%, respectively. ROC analysis for
combined tumor marker P/S ratio showed a very high sensitivity (100%), but relatively low specificity (60.5%) (Fig 3B). The Youden indices for the three above mentioned combinations were 0.76, 0.57 and 0.61, respectively. The Youden index achieved the highest value for the combined four pleural fluid marker measurements compared with those for each single marker, higher than those for the combined serum markers or combined ratio of pleural/serum markers.

**DISCUSSION**

Thoracentesis is a relatively simple and safe procedure which allows obtaining pleural fluid samples in patients with PE. One of the most important components of the routine PE diagnostic work-up is its cytological examination. The mean sensitivity of the cytological examination in subjects with malignant PE is estimated at 60%. This means that in about 40% of malignant PE, the fluid cytology gives a false negative result and does not confirm the malignant origin of the effusion. Thus, to determine the PE etiology, more invasive procedures like closed pleural biopsy or medical thoracoscopy are required. Understandably, attempts have focused on various tumor markers in pleural fluid and serum. However, no single tumor marker with a satisfactory sensitivity and specificity has yet been identified. To increase the diagnostic accuracy of the tumor marker measurements, combinations of selected markers have been studied. These combinations included markers assumed to guarantee the highest probability in the detection of malignancy of different origin and type.

In the present study we chose tumor markers used for detection and monitoring of non-small cell lung carcinoma and mesothelioma (CYFRA 21-1), small cell lung carcinoma (NSE), ovarian (CA-125), and digestive and breast cancers (CEA), trying to cover the main etiologic spectrum of malignant PE. CEA in PE proved to be the marker with the highest diagnostic accuracy. The area under curve (AUC) in the ROC analysis for this parameter was 0.83. Previous studies which included this marker revealed the following AUC values: 0.97; 0.84, and 0.72 [3, 9, 10]. The diagnostic accuracy for serum measurements in our study was lower and equaled to 0.65. In a study by Lee and Chang [10], the AUC for serum CEA concentrations was 0.97, while in that by Romaro et al [9] it was 0.75. The discrepancy may be due to differences in the etiology of the analyzed pleural fluids. The highest diagnostic accuracy was found for patients with lung cancer. CEA is a glycoprotein component of the glycocalyx of the endoderm epithelium, which is abundant in a wide variety of tumors. It has been suggested that increased pleural fluid CEA level may be caused by direct or indirect mechanisms (pleural invasion or decreased lymphatic drainage due to lymphatic obstruction [2, 11]. In the present study, the diagnostic accuracy for the pleural fluid/serum CEA level ratio was 0.84; therefore, it seems that serum CEA measurements do not add relevant diagnostic information.

CYFRA 21-1 is another marker with a high diagnostic yield, but contrary to the three other markers, the serum, rather than plural fluid, level of CYFRA 21-1 shows a higher overall diagnostic accuracy. CYFRA 21-1, soluble fragments of cytokeratin 19, is expressed by all histological types of lung cancer, especially by squamous lung cancer [12]. Similarly to CEA, increased levels of CYFRA 21-1 in the pleural fluid may result from impaired lymphatic drainage or cancer involvement of the pleura. In our study, the AUC for this marker in serum was 0.78. In a series studied by Li et al [13], CYFRA 21-1 serum concentrations of this marker was 0.71 and was comparable to the 0.69 achieved to the present study. It seems, therefore, that CYFRA 21-1 is a valuable marker in the diagnosis of PE related to lung cancer. In our series of the 36 patients with malignant PE, lung cancer was diagnosed only in 6 (16.7%). This may explain why the diagnostic accuracy of CYFRA 21-1 pleural measurements in the present study was relatively low - 41.7%. Studies in which lung cancer was the predominant cause of PE, revealed a higher diagnostic yield of this parameter. Serum CYFRA 21-1 has been found useful for the diagnosis of lung cancer, particularly of the squamous cell type. However, Dejsomritrutai et al [14] found that CYFRA 21-1 is a good marker also in a population of patients with PE caused by adenocarcinoma. These authors reported CYFRA 21-1 sensitivity of 81.5% and 74.1% in serum and the pleural fluid, respectively. The specificity of this marker was also high and reached as much as 97.1% for both serum and PE.

We found a high sensitivity, but low diagnostic accuracy, for NSE. NSE is a known marker of small cell carcinoma. The sensitivity of pleural fluid NSE concentration was as high as 94.4%, while for the serum measurements it was 80.6%. However, the specificity of this marker was relatively low, thus the AUC reached 0.65 for pleural fluid and 0.62 for serum. A similar diagnostic accuracy was observed in previous reports (0.57 and 0.58, respectively) [10]. In the current study, pleural fluid NSE was significantly higher in malignant than benign effusions. The heterogeneity of the investigated subjects does not allow singling out small cell lung cancer related exudates from all PE.

CA-125 is particularly useful in detecting the recurrence of ovarian cancer [15], although the marker is also observed in malignancies of the endometrium, lung, breast, and gastrointestinal tract. In our patients, the accuracy of CA-125 measurement in PE and serum was 0.64 and 0.60, respectively. Other authors report a 37% sensitivity and 100% specificity at a cutoff value of 1000 U/l [2]. To compare this data, we calculated the Youden index. In a study by Ferrer et al [2], the Youden index reached 0.37, while in the present study the respective value was 0.32, which, we believe, is comparable.

Combining the markers may improve the diagnostic accuracy. Ferrer et al [2] achieved 65% sensitivity and 100% specificity for a combination of CYFRA 21-1, CEA, and CA-125 assessed in pleural fluid. The sensi-
tivity of these combined measurements was higher than that of cytological examination (56%) [2]. In the present study, a combination of four markers (CEA, CA-125, CYFRA 21-1, andNSE), with a cut-off for two or more markers, gave sensitivity and specificity of 91.7% and 86.8% for pleural measurements, 86.1% and 71.1% for serum, and 100% and 60.5% for the pleural fluid/serum ratio, respectively. The AUC calculated from the ROC analysis achieved as much as 0.89, 0.82, and 0.88 for the pleural fluid, serum, and pleural fluid/serum ratio, respectively. It seems that the pleural fluid/serum marker ratio does not add any essential clinical information. A meta-analysis by Liang et al. [16] showed similar results with the combinations of different tumor markers, e.g., the AUC for CEA/CA-125 was 0.86 and for CEA/CYFRA 21-1 - 0.93. As it could be expected, the diagnostic yields of different tumor markers evaluated with the Youden index and from the area under the curve in the ROC analysis were similar. The Youden index is a useful parameter enabling a comparative analysis of data found by various authors when single values of sensitivity and specificity are reported. This statistical method was successfully used in the meta-analysis of the usefulness of adenine deaminase and interferon gamma as diagnostic tools in tuberculosis pleurisy [17]. In the present study, the diagnostic yield of the three most accurate markers CEA(P), CEA(R), CYFRA 21-1(P) calculated with the Youden index was virtually the same as assessed with the AUC.

The present study had some limitations. There were relatively small numbers of patients in malignant and non-malignant PE groups. Also, as many as 28 patients were withdrawn from the study because the etiology of the effusion remained unknown. Finally, variability of diseases responsible for PE was rather limited (malignant, parapneumonic, empyemetic, and tuberculous exudates). Nevertheless, we believe we have shown that there are significant differences between the diagnostic value of various PE and serum markers. Overall, pleural fluid markers are superior to serum markers in determining the pleural fluid etiology. A combination of two or more tumor markers may help improve their diagnostic accuracy. However, it seems that measurements of pleural fluid and serum tumor markers play a limited role in the differentiation between malignant and non-malignant PE.

Conflicts of interest: No conflicts of interest were declared in relation to this work.

REFERENCES

[1] Loddenkemper R. Thoracoscopy - state of the art. Eur Respir J 1998; 11: 213-21.
[2] Ferrer J, Villarino MA, Encabo G, Felip E, Bermejo B, Vilà S, Orriols R. Diagnostic utility of CYFRA 21-1, carcinoembryonic antigen, CA 125, neuron specific enolase, and squamous cell antigen level determinations in the serum and pleural fluid of patients with pleural effusions. Cancer 1999; 86: 1488-95.
[3] Porcel JM, Vives M, Esquerda A, Salud A, Pérez B, Rodríguez-Panadero F. Use of a panel of tumor markers (carcinoembryonic antigen, cancer antigen 125, carbohydrate antigen 15-3, and cytokeratin 19 fragments) in pleural fluid for the differential diagnosis of benign and malignant effusions. Chest 2004; 126: 1757-63.
[4] Krenke R, Safianowska A, Paplińska M, Nasilowski J, Dimowska-Sobstyl B, Bogacka-Zatorska E, Jaworski A, Chazar R. Pleural fluid adenosine deaminase and interferon gamma as diagnostic tools in tuberculosis pleurisy. J Physiol Pharmacol 2008; 59 Suppl 6: 349-60.
[5] Sahn SA. Pleural diseases related to metastatic malignancies. Eur Respir J 1997; 10: 1907-13.
[6] Valdés L, Pose À, San José E, Martínez Vázquez JM. Tuberculous pleural effusions. Eur J Intern Med 2003; 14: 77-88.
[7] Hamm H, Light RW. Parapneumonic effusion and empyema. Eur Respir J 1997; 10: 1150-6.
[8] Youden WJ. Index for rating diagnostic tests. Cancer 1950; 3: 32-5.
[9] Romero S, Fernández C, Arriero JM, Espasa A, Candela A, Martín C, Sánchez-Payá J. CEA, CA 15-3 and CYFRA 21-1 in serum and pleural fluid of patients with pleural effusions. Eur Respir J 1996; 5: 17-23.
[10] Lee JH, Chang JH. Diagnostic utility of serum and pleural fluid carcinoembryonic antigen, neuron-specific enolase, and cytokeratin 19 fragments in patients with effusions from primary lung cancer. Chest 2005; 128: 2298-303.
[11] Gu P, Huang G, Chen Y, Zhu C, Yuan J, Sheng S. Diagnostic utility of pleural fluid carcinoembryonic antigen and CYFRA 21-1 in patients with pleural effusion: a systematic review and meta-analysis. J Clin Lab Anal 2007; 21: 398-405.
[12] Lai RS, Chen CC, Lee PC, Lu JY. Evaluation of cytokeratin 19 fragment (CYFRA 21-1) as a tumor marker in malignant pleural effusion. Jpn J Clin Oncol 1999; 29: 421-4.
[13] Li CS, Cheng BC, Ge W, Gao JF. Clinical value of CYFRA21-1, NSE, CA15-3, CA19-9 and CA125 assay in the elderly patients with pleural effusions. Int J Clin Pract 2007; 61: 444-8.
[14] Dejsomritrurai W, Senawong S, Promkiamon B. Diagnostic utility of CYFRA 21-1 in malignant pleural effusion. Respiratory 2001; 6: 213-6.
[15] Osman N, O'Leary N, Mulcahy E, Barrett N, Wallis F, Hickey K, Gupta R. Correlation of serum CA125 with stage, grade and survival of patients with epithelial ovarian cancer at a single centre. Ir Med J 2008; 101: 245-7.
[16] Liang QL, Shi HZ, Qin XJ, Liang XD, Jiang J, Yang HB. Diagnostic accuracy of tumour markers for malignant pleural effusion: a meta-analysis. Thorax 2008; 63: 35-41.
[17] Greco S, Girardi E, Masiangelo R, Capoccieta GB, Saltini C. Adenosine deaminase and interferon gamma measurements for the diagnosis of tuberculous pleurisy: a meta-analysis. Int J Tuberc Lung Dis 2003; 7: 777-86.